PriceTargets.com logo

Genmab A/S - GMAB Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $45.20
  • Forecasted Upside: 93.74%
  • Number of Analysts: 13
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$23.33 As of 10/4/2024 11:55 AM ET
▼ -0.07 (-0.30%)

This chart shows the closing price for GMAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genmab A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMAB

Analyst Price Target is $45.20
▲ +93.74% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is $45.20, with a high forecast of $50.00 and a low forecast of $31.00. The average price target represents a 93.74% upside from the last price of $23.33.

This chart shows the closing price for GMAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 13 polled investment analysts is to hold stock in Genmab A/S. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 10 hold ratings
  • 2 sell ratings
Ratings as of
4/13/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 2 sell ratings
Ratings as of
7/12/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
10/10/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
1/8/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 3 sell ratings
Ratings as of
4/7/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 3 sell ratings
Ratings as of
7/6/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
10/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
9/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
9/11/2024Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$31.00 ➝ $31.00
9/9/2024Truist FinancialLower TargetBuy ➝ Buy$53.00 ➝ $50.00
9/4/2024Morgan StanleyReiterated RatingEqual Weight$31.00
8/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
8/20/2024JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral
8/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
8/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
7/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
7/15/2024Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
6/27/2024BTIG ResearchBoost TargetBuy ➝ Buy$46.00 ➝ $47.00
6/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
6/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
6/4/2024Truist FinancialBoost TargetBuy ➝ Buy$50.00 ➝ $53.00
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
4/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
4/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
3/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
3/26/2024Morgan StanleyReiterated RatingUnderweight ➝ Underweight
3/26/2024Truist FinancialReiterated RatingBuy ➝ Buy$50.00
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
2/23/2024BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$46.00 ➝ $48.00
2/20/2024Truist FinancialReiterated RatingBuy ➝ Buy$54.00 ➝ $50.00
2/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
1/29/2024HC WainwrightBoost TargetBuy ➝ Buy$49.00 ➝ $50.00
1/22/2024CitigroupDowngradeNeutral ➝ Sell
12/6/2023UBS GroupUpgradeNeutral ➝ Buy
11/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$49.00
11/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$49.00
11/10/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
11/8/2023DNB MarketsUpgradeSell ➝ Buy
11/7/2023HC WainwrightLower TargetBuy ➝ Buy$51.00 ➝ $49.00
10/18/2023BNP ParibasInitiated CoverageUnderperform
10/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00
10/13/2023BTIG ResearchBoost TargetBuy ➝ Buy$44.00 ➝ $46.00
10/12/2023Nordea Equity ResearchDowngradeBuy ➝ Hold
9/26/2023Truist FinancialReiterated RatingBuy ➝ Buy$54.00
9/6/2023Truist FinancialReiterated RatingBuy ➝ Buy$54.00
9/6/2023Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
9/5/2023HC WainwrightReiterated RatingBuy ➝ Buy$51.00
8/24/2023BTIG ResearchInitiated CoverageBuy
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy
7/31/2023Morgan StanleyReiterated RatingUnderweight ➝ Underweight
7/31/2023HC WainwrightReiterated RatingBuy ➝ Buy
7/24/2023Morgan StanleyReiterated RatingUnderweight ➝ Underweight
7/14/2023HSBCInitiated CoverageBuy
5/31/2023UBS GroupInitiated CoverageNeutral
5/22/2023HC WainwrightBoost Target$47.00 ➝ $51.00
5/16/2023HC WainwrightBoost Target$46.00 ➝ $47.00
5/12/2023Morgan StanleyInitiated CoverageUnderweight
4/20/2023HC WainwrightReiterated RatingBuy
2/23/2023DanskeUpgradeHold ➝ Buy
2/6/2023Leerink PartnersBoost TargetMarket Perform$33.00 ➝ $36.00
1/3/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight3,450.00 ➝ 3,600.00
12/20/2022CitigroupDowngradeBuy ➝ Neutral
11/17/2022AlphaValueUpgradeReduce
11/15/2022CowenBoost Target$43.00
11/14/2022JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight2,900.00 ➝ 3,450.00
11/14/2022William BlairInitiated CoverageMarket Perform
11/11/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
11/10/2022Leerink PartnersBoost TargetMarket Perform$33.00
10/17/2022DNB MarketsDowngradeBuy ➝ Hold
8/22/2022HC WainwrightBoost TargetBuy$49.00 ➝ $51.00
8/15/2022Morgan StanleyBoost TargetUnderweight$29.00 ➝ $31.00
8/11/2022Leerink PartnersBoost TargetMarket Perform$30.00 ➝ $31.00
7/20/2022HC WainwrightBoost TargetBuy$47.00 ➝ $49.00
6/23/2022BMO Capital MarketsInitiated CoverageMarket Perform$34.73
5/17/2022Morgan StanleyLower TargetUnderweight$29.00
5/13/2022Bryan, Garnier & CoUpgradeSell ➝ Neutral
5/13/2022Berenberg BankUpgradeSell ➝ Hold
5/2/2022CowenInitiated CoverageMarket Perform$38.00
5/2/2022CowenInitiated CoverageMarket Perform
4/12/2022Morgan StanleyLower TargetUnderweight$33.00 ➝ $30.00
3/17/2022HC WainwrightReiterated RatingBuy$47.00
3/16/2022UBS GroupUpgradeNeutral ➝ Buy
2/25/2022JPMorgan Chase & Co.Lower Target3,200.00 ➝ 3,100.00
2/17/2022Leerink PartnersLower TargetMarket Perform$42.00 ➝ $39.00
1/31/2022HC WainwrightUpgradeNeutral ➝ Buy$47.00
1/3/2022GuggenheimDowngradeBuy ➝ Neutral
12/1/2021Berenberg BankInitiated CoverageSell
9/20/2021HC WainwrightReiterated RatingHold$47.00
9/16/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$45.50 ➝ $48.00
9/7/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$37.00
8/24/2021HC WainwrightDowngradeBuy ➝ Neutral$47.00
8/20/2021JPMorgan Chase & Co.Reiterated RatingOverweight
8/16/2021Societe GeneraleReiterated RatingSell
8/12/2021BarclaysReiterated RatingOverweight
8/12/2021UBS GroupReiterated RatingNeutral
8/12/2021Royal Bank of CanadaBoost TargetOutperform$46.00 ➝ $55.00
8/12/2021Leerink PartnersBoost TargetMarket Perform$37.00 ➝ $42.00
7/26/2021HC WainwrightReiterated RatingBuy$47.00
7/19/2021BarclaysReiterated RatingOverweight
7/13/2021HC WainwrightReiterated RatingBuy$47.00
6/9/2021JPMorgan Chase & Co.Reiterated RatingOverweight
6/7/2021UBS GroupReiterated RatingBuy
5/28/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
5/17/2021JPMorgan Chase & Co.Reiterated RatingOverweight
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy
4/19/2021Morgan StanleyLower TargetEqual Weight$41.00 ➝ $37.00
3/15/2021DNB MarketsUpgradeSell ➝ Buy
3/9/2021JPMorgan Chase & Co.Reiterated RatingOverweight
3/9/2021UBS GroupReiterated RatingBuy
2/25/2021Truist FinancialBoost Target$42.00 ➝ $47.00
2/25/2021Leerink PartnersLower TargetMarket Perform$38.00 ➝ $36.00
2/24/2021BarclaysReiterated RatingOverweight
2/24/2021DanskeUpgradeHold ➝ Buy
2/11/2021HC WainwrightReiterated RatingBuy
1/26/2021Leerink PartnersBoost TargetMarket Perform$34.00 ➝ $38.00
1/25/2021DNB MarketsDowngradeHold ➝ Sell
1/19/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight
1/15/2021HC WainwrightBoost TargetBuy$44.00 ➝ $49.00
1/4/2021Royal Bank of CanadaBoost TargetPositive ➝ Outperform$40.00 ➝ $46.00
12/16/2020Morgan StanleyBoost TargetOverweight$37.00 ➝ $41.00
12/9/2020Leerink PartnersLower TargetMarket Perform$36.00 ➝ $34.00
11/25/2020HC WainwrightLower TargetBuy$45.00 ➝ $44.00
11/16/2020UBS GroupReiterated RatingBuy
11/5/2020Morgan StanleyBoost TargetOverweight$35.00 ➝ $37.00
11/5/2020HC WainwrightBoost TargetBuy$42.00 ➝ $45.00
10/27/2020The Goldman Sachs GroupBoost TargetNeutral$37.00
10/13/2020Morgan StanleyBoost TargetOverweight$32.00 ➝ $35.00
9/23/2020HC WainwrightBoost TargetBuy$41.00 ➝ $42.00
9/23/2020Bryan, Garnier & CoDowngradeNeutral ➝ Sell
9/8/2020Leerink PartnersInitiated CoverageMarket Perform$35.00
8/24/2020Truist FinancialBoost Target$39.00 ➝ $41.00
8/21/2020HC WainwrightBoost TargetBuy$40.00 ➝ $41.00
8/13/2020Royal Bank of CanadaBoost TargetOutperform$35.00 ➝ $38.00
8/13/2020Morgan StanleyBoost TargetOverweight$30.00 ➝ $32.00
8/13/2020HC WainwrightReiterated RatingBuy
7/17/2020HC WainwrightReiterated RatingBuy$40.00
7/2/2020Societe GeneraleInitiated CoverageSell
6/30/2020HC WainwrightReiterated RatingBuy$40.00
6/25/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral
6/19/2020Royal Bank of CanadaBoost TargetOutperform$27.00 ➝ $35.00
6/12/2020JPMorgan Chase & Co.Reiterated RatingOverweight
6/11/2020BarclaysReiterated RatingOverweight
6/11/2020SunTrust BanksBoost TargetBuy$36.00 ➝ $39.00
6/11/2020HC WainwrightBoost TargetBuy$34.00 ➝ $40.00
6/3/2020BarclaysReiterated RatingOverweight
6/3/2020Bryan, Garnier & CoDowngradeBuy ➝ Neutral
6/2/2020SunTrust BanksBoost TargetBuy$30.00 ➝ $36.00
6/2/2020DanskeDowngradeBuy ➝ Hold
6/1/2020HC WainwrightReiterated RatingPositive ➝ Buy$29.00 ➝ $34.00
5/26/2020UBS GroupUpgradeNeutral ➝ Buy
5/7/2020SunTrust BanksBoost TargetBuy$28.00 ➝ $30.00
5/7/2020HC WainwrightBoost TargetBuy$28.00 ➝ $29.00
5/1/2020HC WainwrightReiterated RatingBuy$28.00
4/23/2020Credit Suisse GroupInitiated CoverageOutperform
4/15/2020Morgan StanleyLower TargetOverweight$31.00 ➝ $30.00
4/15/2020HC WainwrightLower TargetBuy$29.00 ➝ $28.00
4/6/2020Royal Bank of CanadaReiterated RatingBuy$27.00
3/4/2020HC WainwrightReiterated RatingBuy$29.00
2/24/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $29.00
2/20/2020Morgan StanleyBoost TargetOverweight$30.00 ➝ $31.00
2/11/2020HC WainwrightReiterated RatingBuy$25.00
1/22/2020HC WainwrightReiterated RatingBuy$25.00
1/13/2020SunTrust BanksInitiated CoverageBuy
12/12/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
12/11/2019HC WainwrightReiterated RatingBuy$25.00
12/4/2019HC WainwrightReiterated RatingBuy$25.00
11/20/2019HC WainwrightReiterated RatingBuy$25.00
10/16/2019HC WainwrightBoost TargetBuy$24.00 ➝ $25.00
(Data available from 10/4/2019 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 30 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/8/2024
  • 12 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/7/2024
  • 9 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 10 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 8 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 11 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 12 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024

Current Sentiment

  • 12 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Genmab A/S logo
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $23.33
Low: $23.29
High: $23.42

50 Day Range

MA: $26.65
Low: $23.40
High: $28.48

52 Week Range

Now: $23.33
Low: $23.24
High: $35.88

Volume

130,160 shs

Average Volume

575,230 shs

Market Capitalization

$15.43 billion

P/E Ratio

19.44

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Genmab A/S?

The following Wall Street sell-side analysts have issued reports on Genmab A/S in the last year: BMO Capital Markets, BNP Paribas, BTIG Research, Citigroup Inc., Deutsche Bank Aktiengesellschaft, DNB Markets, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Nordea Equity Research, Royal Bank of Canada, TheStreet, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for GMAB.

What is the current price target for Genmab A/S?

5 Wall Street analysts have set twelve-month price targets for Genmab A/S in the last year. Their average twelve-month price target is $45.20, suggesting a possible upside of 93.7%. Truist Financial Co. has the highest price target set, predicting GMAB will reach $50.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $31.00 for Genmab A/S in the next year.
View the latest price targets for GMAB.

What is the current consensus analyst rating for Genmab A/S?

Genmab A/S currently has 2 sell ratings, 3 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GMAB, but not buy more shares or sell existing shares.
View the latest ratings for GMAB.

What other companies compete with Genmab A/S?

Other companies that are similar to Genmab A/S include Takeda Pharmaceutical, BioNTech, Moderna, BeiGene and Teva Pharmaceutical Industries. Learn More about companies similar to Genmab A/S.

How do I contact Genmab A/S's investor relations team?

Genmab A/S's physical mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The company's listed phone number is (457) 020-2728 and its investor relations email address is [email protected]. The official website for Genmab A/S is www.genmab.com. Learn More about contacing Genmab A/S investor relations.